Spinal Muscular Atrophy Dashboard

View full sample report

A genetic neuromuscular disorder characterized by progressive muscle weakness and atrophy due to degeneration of motor neurons in the spinal cord.

Total WW Revenue of Select Branded Drugs (FY 2025E)
$4,542M
CAGR of Select Branded Drugs (2025-2030)
-3.3%
US Prevalence
4,900-9,301
US List Price Per Patient Per Year
Avg: $971,667 Range: $340,000-$2,125,000

Drug Valuation Analysis

Drug Name Mechanism Company
AI Value ($M)
Download rNPV model
FDA Approved Drugs
3 drugs
Zolgensma
 Gene therapy Novartis
$2377
Evrysdi
 Small molecule: Survival of Motor Neuron 2 Splicing Modifier Roche
$7368
Spinraza
 Oligonucleotide therapies: Survival Motor Neuron-2-directed RNA Interaction Biogen
$5531